1 Av. Irène Joliot-Curie
31100 Toulouse
FRANCE
SmartCatch is lifting the current locks on CTC liquid biopsy by developing a range of compact, portable, easy-to-use products adapted to use in clinical routine, in order to make CTC liquid biopsy accessible and the essential medical procedure for the diagnosis, follow-up and personalization of care in medical oncology.
Circulating tumor cells (CTC) are cancer cells that have escaped from a tumor and migrated through different biofluids in the human body. These tumor cells travel through the bloodstream until they find a suitable niche to proliferate and develop a secondary tumor or metastasis, the leading cause of death by cancer. They therefore carry key information about the presence, nature and aggressiveness of solid tumors.
They convey crucial information in terms of number, genetics, molecular pathways, mechanisms of immune evasion – their detection, counting and analysis could help the oncologist to refine cancer diagnosis and prognosis, adapt the therapy at the individual level and monitor more closely the evolution of the disease over time and the effectiveness of the treatments provided.
Microtechnologies encompasses the scope of new materials, structures with ultimate resolution, and sensors with ultimate sensitivity, where the micron-scale achieved by these cutting-edge technologies meets the scale of CTC.
Circulating Tumor Cells are relatively larger and less deformable than other blood cellular components. Implemented in physiological conditions and low pressure-regimes, our technology exploits these physical traits to isolate them.
The core of the innovation consists in a microengineered capture device, developed with cutting-edge technologies and advanced computational simulations, enabling a one-step physical and selective isolation of CTC from blood in physiological conditions.
Reach out to us !
We develop solutions that meet your needs.
